Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Net Income towards Common Stockholders: 2015-2025

Historic Net Income towards Common Stockholders for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$21.9 million.

  • Seres Therapeutics' Net Income towards Common Stockholders fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.9 million, marking a year-over-year decrease of 169.53%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
  • Seres Therapeutics' Net Income towards Common Stockholders amounted to -$21.9 million in Q3 2025, which was up 10.17% from -$24.3 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Net Income towards Common Stockholders ranged from a high of $139.8 million in Q3 2024 and a low of -$71.2 million during Q1 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$1.2 million, with a median of -$21.9 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' Net Income towards Common Stockholders was 2,144.32% (2024), while the steepest drop was 334.82% (2024).
  • Seres Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$50.0 million in 2021, then plummeted by 37.59% to -$68.8 million in 2022, then soared by 90.51% to -$6.5 million in 2023, then plummeted by 334.82% to -$28.4 million in 2024, then crashed by 115.63% to -$21.9 million in 2025.
  • Its Net Income towards Common Stockholders was -$21.9 million in Q3 2025, compared to -$24.3 million in Q2 2025 and $32.7 million in Q1 2025.